The largest database of trusted experimental protocols

4 protocols using Paclitaxel

Chemotherapeutic agents, such as cisplatin (Accord Healthcare, Milan, Italy), paclitaxel (Accord Healthcare, Milan, Italy), and docetaxel (Hospira, Naples, Italy), were dissolved in 0.9% NaCl and added to the culture medium at the concentrations indicated in Table 1. Curcumin from Curcuma longa (≥95% purity), was purchased from Sigma-Aldrich (St. Louis, MO, USA). A 10 mM stock solution was prepared in dimethylsulfoxide (DMSO, MP Biomedicals, Santa Ana, CA, USA) and stored at +4 °C.
+ Open protocol
+ Expand
After 6 days of culture on 2D and 3D supports, complete medium (including serum) along with the corresponding concentrations of doxorubicin (TEDEC-Meiji Farma, Alcalá de Henares, Spain), paclitaxel (Accord Healthcare Ltd., Thaltej, India), EGCG (Sigma-Aldrich) or G28 were added to the cultures. Following a 48-h treatment, a colorimetric MTT assay (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; Sigma-Aldrich) was used to measure cell viability. More details can be found in SI Appendix.
+ Open protocol
+ Expand
3

Combination Immunotherapy with Paclitaxel, Sunitinib, and Anti-PD-L1 Antibodies

Paclitaxel (Accord Healthcare Inc., DIN: 02391465) was administered at 30 mg/kg, every 2 weeks, intraperitoneally (IP); phosphate-buffered saline (PBS) served as its control. Sunitinib malate (LC Laboratories; administered at 60 mg/kg daily) and its vehicle, formulated as previously described,42 (link) were administered by oral gavage (PO). The therapeutic anti-VEGF agent—a mouse IgG2a antibody against mouse/human VEGF (Genentech, clone B20-4.1.1)—was administered at 5 mg/kg, 2×/week, IP. The two therapeutic antibodies to mouse PD-L1 (also known as CD274 or B7-H1) were a mouse IgG1 raised in PD-L1 knockout mice with a C57BL/6 genetic background (Genentech, clone 6E11; administered at 5 mg/kg, 2×/week, IP) and a rat IgG2b monoclonal antibody (BXCell InVivoMAb #BE0101, clone 10F.9G2; administered at 100 μg/dose, 2×/week, IP)—both antibodies block PD-L1:PD-1 and PD-L1:B7.1 (CD80) interactions. The corresponding InVivoMAb controls from BioXCell were: mouse IgG2a isotype control (#BE0085, clone C1.18.4, unknown specificity), mouse IgG1 isotype control (#BE0083, clone MOPC-21, unknown specificity), and rat IgG2b isotype control (#BE0090, clone LTF-2, anti-keyhole limpet haemocyanin).
+ Open protocol
+ Expand
Olaparib (AZD2281; #S1060), niraparib (MK-4827; #S2741), rucaparib (#AG-014699) veliparib (ABT-888; #S1004), talazoparib (BMN 673; #S7048), phosphate (#S1098), verapamil (CP-16533-1) HCl (#S4202), SN-38 (NK012; #S4908) and MK-571 (#S8126) were purchased from Selleckchem (Munich, Germany). Cisplatin (1 mg/mL), doxorubicin, paclitaxel (6 mg/mL), and topotecan (1 mg/mL) were purchased from Accord Healthcare GmbH (Munich, Germany). Diphenhydramine-hydrochloride (DIPH; D3630-5G), methyl methanesulfonate (MMS; #129925-5G), and treosulfane (Trecondi; #SML1252) were purchased from Sigma Aldrich. Pegylated liposomal doxorubicin (Caelyx) was purchased from Elblandkliniken Stiftung & Co. KG (Riesa, Germany).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!